Type 2 Diabetes

A first-in-class duodenal mucosal resurfacing therapy is associated with reductions in HbA1c and body weight at 24 weeks among a cohort of insulin-treated adults with type 2 diabetes, according to a company press release.

Health insurance policy changes that expand access to continuous glucose monitoring for adults with type 1 or type 2 diabetes can greatly increase uptake of the devices, according to a study published in Diabetes Technology & Therapeutics.

Maintaining a healthy lifestyle — before or after type 2 diabetes diagnosis — was associated with significantly lower risk for microvascular complications for people with the disease, according to study data.

An ED screening program identified patients with undiagnosed prediabetes and type 2 diabetes or undermanaged disease, particularly among racial and ethnic minorities and patients with low income, researchers reported in JAMA Network Open.

Cancer burden among older adults with type 2 diabetes has increased in the past 2 decades while all-cause mortality rates at all ages have decreased, according to a 20-year population-based study published in Diabetologia.

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.

Black and older patients with chronic kidney disease and insured by Medicare are less likely to start SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists than second-generation sulfonylureas, according to data in Kidney Medicine.

The FDA accepted a supplemental new drug application for Jardiance, empagliflozin tablets, which may reduce kidney disease progression and cardiovascular death in adults with chronic kidney disease, according to the press release.

Adults with type 2 diabetes may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to a study published in Nutrition, Metabolism & Cardiovascular Diseases.

Despite the availability of effective prescription therapies for menopausal symptoms, many women delayed seeking treatment, often using nonprescription options instead or no treatment at all, according to researchers.